Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PELI1 | Q96FA3 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4964222 | 0.85 | THRA (0.49) | THRATHRBEPHX1EPHX2 | |
| SCHEMBL4963107 | 0.81 | THRB (0.53) | THRATHRBEPHX1EPHX2 | |
| SCHEMBL4966469 | 0.81 | THRA (0.53) | THRATHRBALDH1A1EPHX1EPHX2 | |
| SCHEMBL4965076 | 0.80 | THRA (0.52) | THRATHRBEPHX1EPHX2 | |
| SCHEMBL4962517 | 0.80 | THRA (0.53) | THRATHRBEPHX1EPHX2 | |
| SCHEMBL4964544 | 0.78 | THRA (0.50) | THRATHRBEPHX1EPHX2 | |
| SCHEMBL4964557 | 0.75 | THRA (0.51) | THRATHRBMEN1KMT2AEPHX1 | |
| SCHEMBL4961772 | 0.75 | THRA (0.57) | THRATHRBALDH1A1 | |
| SCHEMBL4963136 | 0.73 | THRA (0.81) | THRATHRB | |
| SCHEMBL6159248 | 0.73 | MEN1 (0.80) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268404-B1 | MALONAMIC ACIDS AND DERIVATIVES THEREOF AS THYROID RECEPTOR LIGANDS | PFIZER PROD INC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070173548-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | CHIANG YUAN-CHING P | 2007-07-26 | — | — | US | disclosed |
| US-7202275-B2 | Malonamic acids and derivatives thereof as thyroid receptor ligands | WARNER LAMBERT COMPANY LLC (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050209333-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | CHIANG YUAN-CHING P | 2005-09-22 | — | — | US | disclosed |
| US-6924310-B2 | Malonamic acids and derivatives thereof as thyroid receptor ligands | PFIZER INC. (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040077694-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | CHIANG YUAN-CHING P (US) | 2004-04-22 | — | — | US | disclosed |
| US-6664291-B2 | Aromatic amidealkyl acid or ester or amide or hydroxy derivatives are useful in the treatment of obesity, overweight condition, hyperlipidemia, glucoma, cardiac arrhythmias, thyroid disease, skin disoders and diabetes | PFIZER, INC. | 2003-12-16 | — | — | US | disclosed |
| EP-1268404-A1 | MALONAMIC ACIDS AND DERIVATIVES THEREOF AS THYROID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20010051657-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | PFIZER INC. | 2001-12-13 | — | — | US | disclosed |
| WO-2001072692-A1 | MALONAMIC ACIDS AND DERIVATIVES THEREOF AS THYROID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173548-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, TSHR | THRA 1/4885THRB 4/4885MEN1 384/4885 |
| US-20050209333-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, TSHR | THRA 1/4885THRB 4/4885MEN1 384/4885 |
| US-20040077694-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, TSHR | THRA 1/4885THRB 4/4885MEN1 343/4885 |
| US-20010051657-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, THRB | THRA 1/4885THRB 3/4885MEN1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.